Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + pyrotinib
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy consisting of camrelizumab, a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), and pyrotinib, an irreversible pan-HER tyrosine kinase inhibitor. The combination is being investigated primarily for the first-line treatment of advanced or metastatic HER2-positive gastric and gastroesophageal junction (G/GEJ) adenocarcinoma. Camrelizumab acts as an immune checkpoint inhibitor by blocking PD-1, thereby enhancing T-cell mediated anti-tumor immunity. Pyrotinib inhibits multiple members of the human epidermal growth factor receptor (HER) family, including HER2, leading to inhibition of tumor cell proliferation and survival. Clinical studies have shown promising efficacy with this combination in HER2-positive G/GEJ cancer when used with chemotherapy[1][2][3].
- Other names
- camrelizumab + pyrotinibcarrelizumab + pyrrotinib
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on camrelizumab + pyrotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + pyrotinib.